Inspiremd Stock Earnings Reports

InspireMD reported strong Q1 2026 results with revenue of $3.4M, up 122% year-over-year, driven by CGuard global demand and the U.S. launch of CGuard Prime. Management announced a voluntary pause of U.S. commercialization for the CGuard Prime 135 delivery system (in coordination with the FDA) due to technical/physician-experience issues with the delivery system — explicitly not related to the stent implant’s safety or clinical performance. The company is pursuing near-term FDA approval of its original CGuard delivery system (used in >70,000 cases and the C-GUARDIANS trial) and expects that approval in Q3 2026, enabling a relaunch in the U.S. They also expect CGuard Prime 80 for TCAR to be approved in H2 2026 and received FDA clearance to start the C-GUARDIANS III trial for the SwitchGuard neuroprotection system. Due to the voluntary U.S. pause, InspireMD withdrew full-year 2026 revenue guidance and will record Q2 reserves (~$700k customer returns, ~$650k inventory/remediation). Q1 gross profit was $0.7M (20.2% of revenue); adjusted gross margin (ex-impairment) was 34.1%. Net loss was $13.7M and cash + marketable securities totaled $41.6M at March 31, 2026. Management characterizes the pause as temporary and corrective, emphasizes strong international growth and physician demand, and plans to conserve discretionary hiring while continuing R&D and the C-GUARDIANS III trial.